

## EQA round: CC2/24 - Cystatin C

Deadline: 23.8.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D<sub>max</sub> = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>out</sub> = number of the results removed before calculationN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability								
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>(106) Cystatin C</b>	[mg/L]				79							79	74	94	
<b>Sample A</b>		2,19	0,094	4,3	79		CVP	2,19	0,026	23%	1,68	2,7	79	78	99
(1) Abbott		2,22	0,076	3,4	15	0							15		
(46) Erba Lachema		2,19	0,096	4,4	5	0							5		
(60) Roche		2,14	0,077	3,6	31	0							31		
(162) Siemens (Atellica)		2,22	0,069	3,1	13	0							13		
Other					15	1							15		
								3x 3, 2x 58, 3x 91, 1x 140, 2x 149, 4x 179							
<b>Sample B</b>		0,251	0,15	59	79		CVP	0,251	0,041	asym.	0,07	0,43	79	74	94
(1) Abbott		0,104	0,018	17	15	0							15		
(46) Erba Lachema		0,345	0,38	110	5	1							5		
(60) Roche		0,326	0,14	43	31	1							31		
(162) Siemens (Atellica)		0,25	0	0	13	0							13		
Other					15	0							15		
								3x 3, 2x 58, 3x 91, 1x 140, 2x 149, 4x 179							